Compare REBN & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REBN | CALC |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 11.2M |
| IPO Year | 2017 | 2020 |
| Metric | REBN | CALC |
|---|---|---|
| Price | $1.40 | $0.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 75.7K | ★ 309.9K |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | ★ $8,094,628.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.48 |
| Revenue Growth | ★ 36.54 | N/A |
| 52 Week Low | $0.91 | $0.46 |
| 52 Week High | $3.40 | $7.20 |
| Indicator | REBN | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 46.50 |
| Support Level | N/A | $0.52 |
| Resistance Level | $2.02 | $0.77 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 66.31 | 29.45 |
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is a company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in two reportable segments: Reborn Coffee, which includes both the wholesale and retail sales of coffee, water, and other beverages, and Reborn Logistics, which provides freight forwarding services.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.